Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

NCT04731740 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Metastatic Thyroid Gland Carcinoma
Poorly Differentiated Thyroid Gland Carcinoma
Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

Interventions

DRUG: Lenvatinib
BIOLOGICAL: Pembrolizumab
DRUG: Chemotherapy

Sponsor

Saint Petersburg State University, Russia